Search results
Citi holds Buy rating on Mirum stock on positive trial updates By Investing.com
Investing.com· 3 days agoOn Monday, Citi maintained a Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) with a steady price...
Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage...
Benzinga· 3 days agoMonday, Mirum Pharmaceuticals Inc. MIRM announced interim results from two Phase 2b studies...
[VÍDEO] Intervention by Marta Rovira at the National Council of the ERC
Hardwood Paroxysm· 5 days agoWithout Junqueras, who assumes presidential duties as the highest official in the party Marta...
Natural gas conversion project near Williston also includes carbon capture
North Dakota Monitor via Yahoo News· 3 days agoA proposed multi-billion dollar facility to turn natural gas from North Dakota’s oil fields into...
Mirum (MIRM) Soars on Interim Data From Liver Disease Studies
Zacks via Yahoo Finance· 2 days agoMirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients...
Mexican national sentenced for possession of child pornography
The Port Lavaca Wave· 1 day agoA 33-year-old Mexican national residing illegally in the United States has been sentenced for possession of child pornography, announced U.S. Attorney Alamdar S. Hamdani. Juan Francisco Meza-Chavez ...
Diversity, Equity, and Inclusion from a Public Utility Perspective | JD Supra
JD Supra· 1 day agoRegulatory oversight, responsiveness to customers and investors, and a responsibility to provide essential services require a distinct DEI approach. Below is an overview of how state public ...
Public Service Commission Requests Review Of New Federal Energy Policy - West Virginia Public...
West Virginia Public Broadcasting· 7 days agoThe Public Service Commission of West Virginia asked federal administrators Wednesday to reconsider...
Julie Fedorchak continues election winning streak with primary win, says she's just getting started
Grand Forks Herald via Yahoo News· 7 days agoJun. 13—GRAND FORKS — After winning the 2024 Republican U.S. House primary, Julie Fedorchak said her campaign has momentum. "We've really just hit our stride," Fedorchak said. "We have a great ...
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's...
Benzinga· 3 days agoShares of Ovid Therapeutics Inc OVID dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint. Takeda Pharmaceutical Co Ltd TAK announced topline data ...